- Home
- SBFM vs GOVX Comparison
SBFM vs GOVX Comparison
Compare SBFM & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- GOVX
- Stock Information
- Founded
- SBFM 2006
- GOVX 2001
- Country
- SBFM United States
- GOVX United States
- Employees
- SBFM N/A
- GOVX N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- GOVX Health Care
- Exchange
- SBFM Nasdaq
- GOVX Nasdaq
- Market Cap
- SBFM 6.6M
- GOVX 7.6M
- IPO Year
- SBFM N/A
- GOVX N/A
- Fundamental
- Price
- SBFM $1.50
- GOVX $0.70
- Analyst Decision
- SBFM Strong Buy
- GOVX Strong Buy
- Analyst Count
- SBFM 1
- GOVX 3
- Target Price
- SBFM $15.00
- GOVX $10.67
- AVG Volume (30 Days)
- SBFM 44.5K
- GOVX 690.2K
- Earning Date
- SBFM 11-04-2025
- GOVX 11-11-2025
- Dividend Yield
- SBFM N/A
- GOVX N/A
- EPS Growth
- SBFM N/A
- GOVX N/A
- EPS
- SBFM N/A
- GOVX N/A
- Revenue
- SBFM $36,341,741.00
- GOVX $6,143,044.00
- Revenue This Year
- SBFM $32.20
- GOVX N/A
- Revenue Next Year
- SBFM $32.74
- GOVX N/A
- P/E Ratio
- SBFM N/A
- GOVX N/A
- Revenue Growth
- SBFM 19.22
- GOVX 1943.07
- 52 Week Low
- SBFM $1.17
- GOVX $0.43
- 52 Week High
- SBFM $3.90
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- SBFM 56.84
- GOVX 44.16
- Support Level
- SBFM $1.35
- GOVX $0.65
- Resistance Level
- SBFM $1.45
- GOVX $0.73
- Average True Range (ATR)
- SBFM 0.07
- GOVX 0.04
- MACD
- SBFM 0.01
- GOVX -0.00
- Stochastic Oscillator
- SBFM 82.39
- GOVX 33.72
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.